Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial.

Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM.

Ann Intern Med. 2010 Apr 20;152(8):488-96, W174. doi: 10.7326/0003-4819-152-8-201004200-00005.

2.

STATIN-D study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D.

Ertugrul DT, Yavuz B, Cil H, Ata N, Akin KO, Kucukazman M, Yalcin AA, Dal K, Yavuz BB, Tutal E.

Cardiovasc Ther. 2011 Apr;29(2):146-52. doi: 10.1111/j.1755-5922.2010.00141.x.

PMID:
20370794
4.

Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis.

Parker J, Hashmi O, Dutton D, Mavrodaris A, Stranges S, Kandala NB, Clarke A, Franco OH.

Maturitas. 2010 Mar;65(3):225-36. doi: 10.1016/j.maturitas.2009.12.013. Epub 2009 Dec 23. Review.

PMID:
20031348
5.

Relationship of 25-hydroxyvitamin D with all-cause and cardiovascular disease mortality in older community-dwelling adults.

Semba RD, Houston DK, Bandinelli S, Sun K, Cherubini A, Cappola AR, Guralnik JM, Ferrucci L.

Eur J Clin Nutr. 2010 Feb;64(2):203-9. doi: 10.1038/ejcn.2009.140. Epub 2009 Dec 2.

6.

Vitamin D in health and disease: an insight into traditional functions and new roles for the 'sunshine vitamin'.

Borradale D, Kimlin M.

Nutr Res Rev. 2009 Dec;22(2):118-36. doi: 10.1017/S0954422409990102. Review.

PMID:
19900346
7.

Vitamin D and cardiovascular disease.

Giovannucci E.

Curr Atheroscler Rep. 2009 Nov;11(6):456-61. Review.

PMID:
19852887
8.

Vitamin D, parathyroid hormone and the metabolic syndrome in middle-aged and older European men.

Lee DM, Rutter MK, O'Neill TW, Boonen S, Vanderschueren D, Bouillon R, Bartfai G, Casanueva FF, Finn JD, Forti G, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean ME, Pendleton N, Punab M, Silman AJ, Wu FC; European Male Ageing Study Group.

Eur J Endocrinol. 2009 Dec;161(6):947-54. doi: 10.1530/EJE-09-0496. Epub 2009 Sep 22.

9.

Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults.

Ginde AA, Scragg R, Schwartz RS, Camargo CA Jr.

J Am Geriatr Soc. 2009 Sep;57(9):1595-603. doi: 10.1111/j.1532-5415.2009.02359.x. Epub 2009 Jun 22.

PMID:
19549021
10.

Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins?

Yavuz B, Ertugrul DT, Cil H, Ata N, Akin KO, Yalcin AA, Kucukazman M, Dal K, Hokkaomeroglu MS, Yavuz BB, Tutal E.

Cardiovasc Drugs Ther. 2009 Aug;23(4):295-9. doi: 10.1007/s10557-009-6181-8.

PMID:
19543962
11.

Vitamin D deficiency and its correlations with increased cardiovascular incidences.

Sood A, Arora R.

Am J Ther. 2010 Jul-Aug;17(4):e105-9. doi: 10.1097/MJT.0b013e31819e9e88.

PMID:
19451805
12.

Vitamin D and type 2 diabetes: Is there a link?

Chowdhury TA, Boucher BJ, Hitman GA.

Prim Care Diabetes. 2009 May;3(2):115-6. doi: 10.1016/j.pcd.2009.03.004. Epub 2009 Apr 23.

PMID:
19395331
13.

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group.

Lancet. 2009 Apr 4;373(9670):1175-82. doi: 10.1016/S0140-6736(09)60447-5. Epub 2009 Mar 28.

PMID:
19329177
14.

Vitamin D and mortality in older men and women.

Pilz S, Dobnig H, Nijpels G, Heine RJ, Stehouwer CD, Snijder MB, van Dam RM, Dekker JM.

Clin Endocrinol (Oxf). 2009 Nov;71(5):666-72. doi: 10.1111/j.1365-2265.2009.03548.x. Epub 2009 Feb 18.

PMID:
19226272
15.

25-Hydroxyvitamin d and risk of stroke: possible mediation by statin therapy?

Lee P, Greenfield JR.

Stroke. 2009 Feb;40(2):e35; author reply e37-8. doi: 10.1161/STROKEAHA.108.537167. Epub 2008 Dec 18. No abstract available.

16.

The role of cholesterol and statins in stroke.

Navi BB, Segal AZ.

Curr Cardiol Rep. 2009 Jan;11(1):4-11. Review.

PMID:
19091169
17.

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group.

N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.

18.

Vitamin D: criteria for safety and efficacy.

Heaney RP.

Nutr Rev. 2008 Oct;66(10 Suppl 2):S178-81. doi: 10.1111/j.1753-4887.2008.00102.x. Review.

PMID:
18844846
19.

Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis.

Petretta M, Costanzo P, Perrone-Filardi P, Chiariello M.

Int J Cardiol. 2010 Jan 7;138(1):25-31. doi: 10.1016/j.ijcard.2008.08.001. Epub 2008 Sep 14.

PMID:
18793814
20.

Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence.

Schwartz JB.

Clin Pharmacol Ther. 2009 Feb;85(2):198-203. doi: 10.1038/clpt.2008.165. Epub 2008 Aug 27.

PMID:
18754003

Supplemental Content

Support Center